Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Blood (2025) 146 (Supplement 1): 681.

https://doi.org/10.1182/blood-2025-681

Published: 2025

Journal Articles

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 680.

https://doi.org/10.1182/blood-2025-680

Published: 2025

Journal Articles

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Blood (2025) 146 (Supplement 1): 89.

https://doi.org/10.1182/blood-2025-89

Published: 2025

Journal Articles

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 3301.

https://doi.org/10.1182/blood-2025-3301

Published: 2025

Journal Articles

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Roberta S. Azevedo, Caitlin Rausch, Alexis Geppner, Francisco Vega, Deepa Sampath, Alessandra Ferrajoli, Kelly Chien, Elias Jabbour, Danielle Hammond, Nicholas Short, Koichi Takahashi, Nitin Jain, Jan Burger, Gautam Borthakur, William Wierda, Chitra Hosing, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2025-3653

Published: 2025

Journal Articles

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Vanthana Bharathi, Kristofer Jennings, Jackie Broadway-Duren, Mahesh Swaminathan, Nitin Jain, William Wierda, Jan Burger, Dervy Salcedo, Stephanie Zelaya, Margaret Pace, Mariela Sivina, Alessandra Ferrajoli

Blood (2025) 146 (Supplement 1): 517.

https://doi.org/10.1182/blood-2025-517

Published: 2025

Journal Articles

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Mahesh Swaminathan, Nitin Jain, Alexandra Lovell, Ashley Dinh, Alessandra Ferrajoli, Jan Burger, Musa Yilmaz, Tapan Kadia, Lucia Masarova, Yesid Alvarado Valero, Prithviraj Bose, Farhad Ravandi, Koji Sasaki, Wei Qiao, Zhouxuan Li, Naveen Garg, Michael Keating, William Wierda

Blood (2025) 146 (Supplement 1): 5687.

https://doi.org/10.1182/blood-2025-5687

Published: 2025

Journal Articles

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Alexandra Lovell, Emily Lee, Mikaela McCabe, Nitin Jain, Alessandra Ferrajoli, Mahesh Swaminathan, Jan Burger, William Wierda

Blood (2025) 146 (Supplement 1): 5685.

https://doi.org/10.1182/blood-2025-5685

Published: 2025

Journal Articles

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Caitlin Rausch, Gautam Borthakur, Fadi Haddad, Kelly Chien, Danielle Hammond, Guillermo Montalban-Bravo, Naveen Pemmaraju, Lucia Masarova, Musa Yilmaz, Michael Andreeff, Elias Jabbour, Jan Burger, Nitin Jain, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3457.

https://doi.org/10.1182/blood-2025-3457

Published: 2025

Journal Articles

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Blood (2016) 128 (22): 177.

https://doi.org/10.1182/blood.V128.22.177.177

Published: 2016

Journal Articles

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

Maro Ohanian, DO, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD, Naval Daver, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Mark Brandt, BS, Sherry Pierce, BSN, BA, Jan Burger, MD PhD, Mary Ann Richie, Keyur Patel, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2016) 128 (22): 1611.

https://doi.org/10.1182/blood.V128.22.1611.1611

Published: 2016

Journal Articles

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Steven Coutre, MD, John C. Byrd, MD, Peter Hillmen, Jacqueline C. Barrientos, MD, Paul M. Barr, Stephen Devereux, PhD FRCP, FRCPath, Tadeusz Robak, MD PhD, Thomas J. Kipps, MD, PhD, Anna Schuh, MDPhD, Carol Moreno, MD, Richard R. Furman, Jan Burger, MD PhD, Michael O'Dwyer, MD, Paolo Ghia, Rudolph Valentino, PharmD, Samuel Suzuki, MS, MBA, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, Susan M. O'Brien, MD

Blood (2016) 128 (22): 4383.

https://doi.org/10.1182/blood.V128.22.4383.4383

Published: 2016

Journal Articles

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Preetesh Jain, MBBS, MD DM, PhD, Philip A Thompson, MBBS, Michael Keating, MBBS, Zeev Estrov, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Hagop M. Kantarjian, MD, Jan Burger, MD PhD, Susan M. O'Brien, MD, William G. Wierda, MD PhD

Blood (2016) 128 (22): 4390.

https://doi.org/10.1182/blood.V128.22.4390.4390

Published: 2016

Journal Articles

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Blood (2016) 128 (22): 234.

https://doi.org/10.1182/blood.V128.22.234.234

Published: 2016

Journal Articles

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Susan M. O'Brien, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD PhD, Jan Burger, MD PhD, Kristie Blum, MD, Jeff Sharman, MD, William G. Wierda, MD PhD, Jeffrey Jones, MD MPH, Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Ying Luan, PhD, Danelle F. James, MD MAS, Alvina D. Chu, MD, John C. Byrd, MD

Blood (2016) 128 (22): 233.

https://doi.org/10.1182/blood.V128.22.233.233

Published: 2016

Journal Articles

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Dan A. Landau, MD PhD, Clare Sun, MD, Daniel Rosebrock, Mariela Campbell, Sarah E. M. Herman, PhD, Julia Hoellenriegel, MS, Mohammed Farooqui, Wandi Zhang, MD, Donna S. Neuberg, ScD, Dimitri Livitz, Ignaty Leshchiner, Gad Getz, PhD, Jan Burger, MD PhD, Adrian Wiestner, MD PhD, Catherine J Wu, MD

Blood (2016) 128 (22): 188.

https://doi.org/10.1182/blood.V128.22.188.188

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Princy Yohannan Sam, MD, Hycienth Ahaneku, MDPhD, Graciela M. Nogueras-Gonzalez, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD PhD, Naval Daver, MD, Tapan Kadia, MD, Jan Burger, MD PhD, Sherry Pierce, BSN, BA, Courtney D DiNardo, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2016) 128 (22): 1919.

https://doi.org/10.1182/blood.V128.22.1919.1919

Published: 2016

Journal Articles

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

Jennifer A. Woyach, MD, Peter Hillmen, Jennifer R. Brown, MD PhD, Steven E. Coutre, MD, Paul Barr, MD, Susan M. O'Brien, MD, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD FRCP, FRCPath, Neil E. Kay, MD, Nishitha Reddy, MD MSCI, MBBS, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Alessandra Tedeschi, Cathy Zhou, MS, Joi Ninomoto, PharmD, Danelle F. James, MD MAS, John C. Byrd, MD, Jan Burger, MD PhD

Blood (2016) 128 (22): 2041.

https://doi.org/10.1182/blood.V128.22.2041.2041

Published: 2016

Journal Articles

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Shih-Shih Chen, PhD, Steven Ham, Priyadarshini Ravichandran, Ileana D'Aloisio, Emily Kate Butera, Romi Lyallpuri, Yasmine Kieso, Jacqueline C. Barrientos, MD, Kanti R Rai, Jan Burger, MD PhD, Nicholas Chiorazzi, MD

Blood (2016) 128 (22): 5586.

https://doi.org/10.1182/blood.V128.22.5586.5586

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia

Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial

Dose and BTK occupancy relationship in the prospective Phase 2 TAILOR study: Exploratory end point analysis of the ibrutinib monotherapy cohorts in patients with previously untreated chronic lymphocytic leukemia

Venetoclax-based therapies in patients with Relapsed/Refractory T-cell prolymphocytic leukemia

Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: A prospective cohort study and quality improvement initiative (2019–2025)

Target dose delivery comparison: Ibrutinib + venetoclax vs. acalabrutinib + venetoclax in treatment-Naïve CLL patients in prospective clinical trials

Venetoclax initiation monitoring and interventions after acalabrutinib lead-in for chronic lymphocytic leukemia

Cladribine-based low-intensity therapy is safe and effective in patients with newly diagnosed Acute Myeloid Leukemia (AML) and renal impairment

Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated Adult T-Cell Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma

Combination of Sorafenib and 5-Azacytidine in Older Patients with Untreated Acute Myeloid Leukemia with FLT3 -ITDmutation

Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Causes of Discontinuation and Long-Term Outcomes of Patients with CLL after Discontinuing Ibrutinib

Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)

Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2)

In Vivo Evidence of in Situ Cell Death Preferentially Occurring in CLL Patients with Minimal Lymphocytosis By the Diminished BCL2 and Loss of T Cell Support after Ibrutinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only